Introduction
============

Primary sclerosing cholangitis (PSC) is a rare, idiopathic disease with a prevalence of 13.6 per 100 000 persons \[[@gou085-B1]\]. It is characterized by inflammation, fibrosis, and strictures of the biliary tree \[[@gou085-B1]\]. PSC has long been reported as occurring in association with ulcerative colitis (UC) \[[@gou085-B4]\]. Studies have demonstrated that 44--90% of patients with PSC have underlying UC \[[@gou085-B1], [@gou085-B7], [@gou085-B8]\]; however, as few as 5% of patients with UC will simultaneously develop PSC \[[@gou085-B8]\]. Some writers have proposed that PSC coinciding with inflammatory bowel disease (IBD) may represent a unique phenotype of IBD, distinct from UC and Crohn's disease \[[@gou085-B3], [@gou085-B9]\].

Patients with PSC often progress to cirrhosis \[[@gou085-B2]\]. While the definitive treatment is liver transplantation \[[@gou085-B3], [@gou085-B10], [@gou085-B11]\], patients may receive a transjugular intrahepatic portosystemic shunt (TIPS) to manage symptoms such as bleeding esophageal varices, parastomal varices and portal hypertension \[[@gou085-B12], [@gou085-B13]\]. Placement of TIPS has been shown to be a minimally invasive and effective means of controlling variceal bleeding, ascites and portal hypertension \[[@gou085-B12], [@gou085-B14]\].

Patients with PSC and UC also frequently undergo colectomy for the management of UC-related symptoms and complications \[[@gou085-B17]\]. Studies have also found that patients with PSC and UC are at high risk for colon cancer \[[@gou085-B18], [@gou085-B19]\]. In addition, colectomy has been demonstrated to be protective against recurrence of PSC following liver transplantation \[[@gou085-B20], [@gou085-B21]\].

In patients with UC who undergo colectomy, long-term quality of life is considered to be equivalent to that of the normal healthy population \[[@gou085-B22]\]; however common post-operative complications of patients with UC undergoing colectomy include wound infection, ileus, bleeding, and the formation of fistulae \[[@gou085-B23], [@gou085-B24]\]: major complication rates as high as 27% have been reported \[[@gou085-B25]\]. It has been suggested that placement of a TIPS prior to abdominal surgery in cirrhotic patients may improve surgical outcomes \[[@gou085-B26]\]; however, there are contradictory studies that found no difference in outcomes \[[@gou085-B27]\].

The aim of our study was to determine, in patients who underwent colectomy for the treatment of PSC associated with UC, whether TIPS prior to the colectomy altered their rates of post-operative complications.

Materials and methods
=====================

Data source
-----------

This is a retrospective chart review, approved by our hospital institutional review board (IRB). Data was collected from previously established data base, of all patients undergoing TIPS at our institution from period of 2001 to 2011. This data base was established retrospectively by our department of interventional radiology at Cleveland clinic and includes patient demographic information, indication of TIPS and procedure date.

Inclusion and exclusion criteria
--------------------------------

Patients were included if they underwent colectomy after being diagnosed with PSC and UC at our institution from 2001 to 2011. This was determined using International Classification of Diseases 9^th^ Revision (ICD-9) codes. Patients were excluded from the Study group if they underwent TIPS after colectomy. Patients who met the selection criteria were then divided into two groups: those who had undergone TIPS prior to colectomy (the Study group) and those not having undergone TIPS (the Control group).

Variables
---------

Demographic information was obtained from the above-mentioned database, including age, gender, race, alcohol use, tobacco use, hepatitis B virus (HBV) and hepatitis C virus (HCV) status, family history of inflammatory bowel disease (IBD), and body mass index (BMI). Information on PSC and UC characteristics was obtained, including duration of PSC, the use of various medical therapies, albumin levels, total bilirubin levels, liver function tests \[including aspartate aminotransferase (AST) and alanine aminotransferase (ALT)\], alkaline phosphatase (ALP), blood urea nitrogen (BUN), serum creatinine, hemoglobin, platelet counts, international normalized ratio (INR), activated partial thromboplastin time (APTT), and the model for end-stage liver disease score (MELD). The Mayo Risk Score system was used to evaluate the severity of PSC \[[@gou085-B28]\].

Information related to colectomy was obtained, including duration of UC at time of colectomy, the indication for colectomy, restoration, and type of ileostomy. Information related to TIPS was obtained, including time from TIPS to colectomy and clinical indication.

Outcomes of interest
--------------------

Our primary outcome of interest was post-operative complications following colectomy and whether or not placement of TIPS affected these complications. Complications examined included hypotension, desaturation, bleeding requiring transfusions, re-admission within 30 days, reason for re-admission, ileus, obstruction, wound infection, wound dehiscence, abdominal abscess, pelvic abscess, deep vein thrombosis, proximal vein thrombosis, septicemia, peritonitis, anastomotic leakage, fistula, worsening liver function tests, coagulopathy, pulmonary complications, urinary complications, emergency re-operation, and mortality.

Statistical analysis
--------------------

Univariate analysis was performed to assess differences between subjects with and without TIPS. Either analysis of variance or the non-parametric Kruskal-Wallis test were used for continuous variables, and Fisher's exact test or Pearson's chi-squared test was used for categorical factors. A *P \< *0.05 was considered statistically significant. SAS (version 9.2, The SAS Institute, Cary, NC) was used for all analyses. Data are presented as mean ± standard deviation, median (25th, 75th percentiles) or *n* (%).

Results
=======

A total of 50 patients with PSC and UC underwent colectomy. Of these, 13 received a TIPS (the Study group), while 37 did not (the Control group). Four of the 13 TIPS were performed after colectomy and were therefore excluded, leaving 9 patients in the Study group ([Figure 1](#gou085-F1){ref-type="fig"}). Figure 1.Algorithm of case selection

Clinical characteristics
------------------------

The Study group and the Control group did not significantly differ in terms of age, gender, race, smoking status, alcohol use, HBV status, HCV status, family history of IBD, BMI, or prevalence of obesity ([Table 1](#gou085-T1){ref-type="table"}). Table 1.Demographics and medical historyFactor*n*[\*](#gou085-TF2){ref-type="table-fn"}No TIPS (*n = *37)TIPS (*n = *9)*P*-valueAge at colectomy (years)4543.4 ± 14.047.8 ± 10.00.41Male4627 (73.0)7 (77.8)0.77 Race460.99F Caucasian35 (94.6)9 (100.0)African-American2 (5.4)0 (0.0)Alcohol3913 (40.6)0 (0.0)0.073FSmoking4010 (30.3)3 (42.9)0.66FHuman immunodeficiency virus150 (0.0)0 (0.0)Hepatitis B virus231 (5.9)1 (16.7)0.46FHepatitis C virus230 (0.0)0 (0.0)Family H/O IBD437 (19.4)2 (28.6)0.59Body mass index (kg/m^2^)3627.4 ± 6.624.9 ± 4.00.39Obesity367 (23.3)0 (0.0)0.32F[^1][^2][^3]

There were a number of significant differences in PSC characteristics between the two groups ([Table 2](#gou085-T2){ref-type="table"}). Patients in the Study group had higher median Mayo Risk Scores (1.5) *vs.* the Control group (0.20) (*P = *0.001). Mean albumin levels were significantly lower in the Study group (2.8 g/dL) *vs.* the Control group (3.8 g/dL) (*P \< *0.001). Mean total bilirubin was higher in the Study group (2.3 mg/dL) *vs.* the Control group (0.8 mg/dL) (*P = *0.011). The Study group also had lower hemoglobin (*P \< *0.001) and platelet levels (*P = *0.005), higher INR values (*P = *0.026) and MELD scores (*P \< *0.001) and longer APTT (*P = *0.045). Table 2.Characteristics of primary sclerosing cholangitisFactor*n*[\*](#gou085-TF5){ref-type="table-fn"}No TIPS (*n = *37)TIPS (*n = *9)*P*-valueDuration of PSC at colectomy (years)317.0 (2.0, 15.0)3.5 (2.0, 4.5)0.31Severity- Mayo Risk Score400.20 (−0.64, 0.77)1.5 (0.85, 2.4)*0.001*Albumin (g/dL)403.8 ± 0.662.8 ± 0.55*\<0.001*Total bilirubin (mg/dL)400.80 (0.50, 1.3)2.3 (1.1, 4.8)*0.011*Aspartate aminotransferase (U/L)4053.0 (27.0, 78.0)51.0 (36.0, 68.0)0.97Alanine aminotransferase (U/L)3949.5 (25.5, 83.5)41.0 (19.0, 118.0)0.71Alkaline phosphatase (U/L)40227 (123, 387)410 (249, 497)0.29Blood urea nitrogen (mg/dL)4111.0 (10.0, 18.0)15.0 (12.0, 19.0)0.21Serum creatinine (mg/dL)410.92 ± 0.340.78 ± 0.280.3Hemoglobin (g/dL)4112.7 ± 1.99.8 ± 0.90*\<0.001*Platelets (×10^9^/L)40329.4 ± 143.6148.5 ± 95.6*0.005*International normalized ratio371.03 ± 0.251.3 ± 0.30*0.026*Activated partial thromboplastin time(s)3430.7 ± 3.535.1 ± 8.2*0.045*MELD score378.2 ± 2.713.8 ± 5.0*\<0.001*[^4][^5][^6]

The two groups did not significantly differ in duration of UC at time of colectomy, pre-colectomy treatment, or indications for colectomy; however, patients in the Control group were more likely to undergo restoration (94.6%) than those in the study group (42.9%) (*P \< *0.001). Those in the Study group were also more likely to undergo end-type ileostomy, instead of loop-type ileostomy ([Table 3](#gou085-T3){ref-type="table"}). Table 3Ulcerative colitis and colectomy characteristicsFactor*n*[\*](#gou085-TF8){ref-type="table-fn"}No TIPS (*n = *37)TIPS (*n = *9)*P*-valueDuration of UC at colectomy (years)4018.0 (13.0, 33.0)25.5 (15.0, 30.0)0.56Pre-colectomy treatment (non-exclusive)31 Anti-inflammatory treatment18 (66.7)4 (100.0)0.30F Steroids23 (85.2)3 (75.0)0.52F Immunomodulators7 (25.9)2 (50.0)0.56FIndication for colectomy (non-exclusive)44 Refractory to medications13 (35.1)4 (57.1)0.40F Dysplasia19 (51.4)3 (42.9)0.99F Carcinoma3 (8.1)0 (0.0)0.99F Adenomatous polyps2 (5.4)1 (14.3)0.41FRestoration4435 (94.6)3 (42.9)*\<0.001*Type of restoration380.99F IPAA33 (94.3)3 (100.0) Ileorectal2 (5.7)0 (0.0)Ileostomy4535 (94.6)8 (100.0)0.99FType of ileostomy42*\<0.001* Loop33 (94.3)3 (42.9) End2 (5.7)4 (57.1)Post-operative complications4637 (100.0)8 (88.9)0.20F Bleeding446 (16.2)1 (14.3)0.9 Ileus448 (21.6)1 (14.3)0.66 Obstruction442 (5.4)0 (0.0)0.99F Wound infection444 (10.8)3 (42.9)*0.034* Wound dehiscence440 (0.0)2 (28.6)*0.022F* Abdominal abscess442 (5.4)2 (28.6)0.11F Pelvic abscess446 (16.2)1 (14.3)0.9 Deep venous thrombosis440 (0.0)0 (0.0) Portal vein thrombosis461 (2.7)0 (0.0)0.99F Septicemia442 (5.4)1 (14.3)0.41F Peritonitis440 (0.0)0 (0.0) Anastomotic leak444 (10.8)1 (14.3)0.99F Fistula440 (0.0)1 (14.3)0.16F Worsening liver function tests442 (5.4)0 (0.0)0.99F Coagulopathy441 (2.7)0 (0.0)0.99F Pulmonary complications440 (0.0)1 (14.3)0.16F Urinary complications441 (2.7)0 (0.0)0.99F Other complication371 (2.7)0 (0.0)0.99FBlood transfusions requested421 (2.8)2 (33.3)*0.049F*No. of blood transfusion38*0.001* 033 (94.3)1 (33.3) 11 (2.9)1 (33.3) 40 (0.0)1 (33.3) 51 (2.9)0 (0.0)Hospital stay (days)445.0 (5.0, 8.0)8.0 (7.0, 23.0)*0.041*Re-admission within 30 days447 (18.9)4 (57.1)*0.032*Reason for re-admission (non-exclusive)11 Nausea/vomiting0 (0.0)1 (25.0)0.36F Renal failure1 (14.3)0 (0.0)0.99F Infection4 (57.1)3 (75.0)0.99F Wound dehiscence1 (14.3)0 (0.0)0.99F Bowel obstruction1 (14.3)0 (0.0)0.99FEmergency re-operation452 (5.4)0 (0.0)0.99FPost-operative mortality460 (0.0)1 (11.1)0.20F[^7][^8][^9]

Patients underwent placement of a TIPS a median of 2.3 (interquartile 0.68--18.6) months before colectomy. Clinical indications were portal hypertension in six patients, variceal bleeding in one, ascites in one, and "not listed" for one patient.

Post-operative complications
----------------------------

As illustrated in [Table 3](#gou085-T3){ref-type="table"}, patients who underwent TIPS experienced several complications, with greater frequency than the Control group. The Study group had more intra-operative bleeding---requiring more blood transfusions (*P = *0.049)---more wound infections (*P = *0.034), a higher risk of wound dehiscence (*P = *0.022), and a higher chance of re-admission within 30 days (*P = *0.032). Post-operative mortality did not differ significantly.

Discussion
==========

To the best of our knowledge, this is the first study of its kind to examine the effect of TIPS prior to colectomy in patients with both PSC and UC. Previous studies have examined the effect of TIPS prior to abdominal surgery in general, with conflicting results; however, these studies examined patients with a variety of diseases undergoing a variety of surgical procedures, while we focused on a specific subset of IBD population (PSC and UC) undergoing one procedure ( Colectomy). \[[@gou085-B26], [@gou085-B27]\].

It has been proposed that, in cirrhotic patients, decompression of the portal system through the placement of TIPS prior to abdominal surgery improves surgical outcomes \[[@gou085-B26]\]. It has been suggested that, because the TIPS procedure is minimally invasive and successfully reduces portal hypertension---a contra-indication to many abdominal surgeries---it should be used prior to surgery in a two-step process \[[@gou085-B26]\]. This claim was based on a study of experiences with seven severely cirrhotic patients, three of whom underwent surgery of the colon \[[@gou085-B26]\].

However, other studies have disagreed with these findings. A retrospective examination of the effect of pre-surgery TIPS on patients with cirrhosis undergoing abdominal surgery found that pre-operative TIPS placement did not affect survival, nor did it cause significant differences in post-operative complications \[[@gou085-B27]\]. Their study population consisted of 10 patients undergoing colectomy, five undergoing antrectomy, one small-bowel resection, one pancreatectomy, and one nephrectomy while, in the control population of 18 patients, 13 underwent colectomy \[[@gou085-B26]\].

These earlier studies led us to hypothesize that TIPS placement prior to colectomy might at best improve outcomes, or at worst offer no significant benefit. It was therefore unexpected that placement of a TIPS was associated with increased intra-operative and post-operative complications.

Our findings suggest that the cause was not the presence of TIPS, but rather that patients in the Study group had more severe cirrhosis, which made both TIPS placement and post-colectomy complications more likely. This agrees with the PSC characteristics of the Study group described above, such as increased Mayo Risk Score, decreased serum albumin, increased total bilirubin, increased INR, increased APTT, and increased MELD score, all of which suggest more severe cirrhosis. This suggests that patients with severe disease, who undergo TIPS, are still at risk of worse outcomes than patients with mild disease, irrespective of the presence or absence of TIPS.

The increased INR and APTT explain the increased intra-operative bleeding requiring blood transfusions. The increased rate of wound infections seen in the Study group may also be the result of more severe cirrhosis. Various studies have shown that patients with cirrhosis are likely to acquire secondary infections while hospitalized \[[@gou085-B29], [@gou085-B30]\]; it is thought that patients with cirrhosis have impaired immune function \[[@gou085-B31]\]. Studies have also suggested that patients with cirrhosis produce less glutathione, which increases their risk of infection \[[@gou085-B32], [@gou085-B33]\]. It is also possible that those in the Study group were taking higher doses of immunomodulators; this could not be ascertained, as we only looked at use of immunomodulators as a categorical variable.

Wound infection has been shown to be a major risk factor in the development of wound dehiscence following abdominal surgery, through the increased presence of neutrophils and matrix metalloproteinases \[[@gou085-B34]\]. This may explain the increased rate of wound dehiscence observed in our Study group. The higher rates of wound infection and dehiscence offer an explanation for the increased re-admissions within 30 days.

This study is limited by its retrospective nature and the use of databases, which may have introduced further confounding factors such as incorrect coding. We were also limited by the fact that we were examining a rare disease: out of our entire database, we were only able to find nine patients to include in the Study group, which may not have been large enough to provide sufficient power to detect all complications. Data on liver transplantation and dosing regimens of immunosuppressive medications might have been useful but were not available. In addition, this is a single-institutional study, which limits the general applicability of our findings.

In conclusion, our findings suggest that patients who underwent TIPS placement had more severe cirrhosis, which led to an increase in intra-operative and post-operative complications. But what remains unclear is whether TIPS placement may have exacerbated or diminished these complications. Based on our initial findings, prospective tracking of patients with PSC and UC undergoing colectomy following TIPS may be warranted.
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[^1]: Values presented as Mean ± SD with ANOVA or *n* (%) with Fisher\'s Exact test (F) or otherwise Pearson\'s chi-squared test.

[^2]: \*Partial data are not available in some cases.

[^3]: TIPS = transjugular intrahepatic portosystemic shunt; IBD = inflammatory bowel disease.

[^4]: Values presented as Mean ± SD with ANOVA; Median (P25, P75) with Kruskal-Wallis test.

[^5]: \*Partial data are not available in some cases.

[^6]: TIPS = transjugular intrahepatic portosystemic shunt; MELD = Model for end-stage liver disease

[^7]: Values presented as Median \[P25, P75\] with Kruskal-Wallis test, or *n* (%) with Fisher\'s Exact test (F) or otherwise Pearson\'s chi-squared test.

[^8]: \*Partial data are not available in some cases.

[^9]: TIPS = transjugular intrahepatic portosystemic shunt; IPAA = ideal pouch-anal anastomosis
